Find stories of hope, told by the people who motivate us every day to continue changing the standard in cancer care.
Each cell therapy we develop is uniquely designed for each patient, harnessing the power of the immune system to target and attack cancer. Our CAR T-cell therapy manufacturing process includes these 5 steps:
September 18, 2023Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
June 22, 2023Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan